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Purpose: In spite of increased rates of complete response to initial chemotherapy, most patients with advanced
ovarian cancer relapse and succumb to progressive disease.
Rationale: Genetically reprogrammed, patient-derived chimeric antigen receptor (CAR)-T lymphocytes with the
ability to recognize predefined surface antigens with high specificity in a non-MHC restricted manner have shown
increasing anti-tumor efficacy in preclinical and clinical studies. Folate receptor-α (FRα) is an ovarian cancer-specific
tumor target; however, it is expressed at low levels in certain organs with risk for toxicity.
Design: Here we propose a phase I study testing the feasibility, safety and preliminary activity of FRα-redirected
CAR-T cells bearing the CD137 (4-1BB) costimulatory domain, administered after lymphodepletion for the treatment
of recurrent ovarian cancer. A novel trial design is proposed that maximizes safety features.
Innovation: This design involves an initial accelerated dose escalation phase of FR-α CAR-T cells followed by a
standard 3 + 3 escalation phase. A split-dose approach is proposed to mitigate acute adverse events. Furthermore,
infusion of bulk untransduced autologous peripheral blood lymphocytes (PBL) is proposed two days after CAR-T cell
infusion at the lower dose levels of CAR-T cells, to suppress excessive expansion of CAR-T cells in vivo and mitigate
toxicity.Background and rationale
Adoptive T cell therapy in ovarian cancer
Ovarian cancer is the fifth most common cancer in
women, affecting one of every 55 women. There are
about 21,650 new cases annually in the United States,
with 15,520 deaths estimated in 2008 [1] making ovarian
cancer the most common cause of death from gynecolo-
gic malignancy. While there have been improvements in
the treatment of epithelial ovarian cancer, most patients
present with Stage III or IV disease, which has a 5-year
survival rate of less than 25% [2-4]. New approaches are
needed to improve the outcome of these women [5].
Adoptive immunotherapy is one of the most robust
forms of immunotherapy for the treatment of estab-
lished tumors [6]. Early cell transfer trials in ovarian
cancer have been promising: In one such trial, adminis-
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reproduction in any medium, provided the or(TILs) to ovarian cancer patients after surgical resection
and cisplatin chemotherapy resulted in prolonged
disease-free survival and increased the 3-year survival
rate, supporting the notion that T cell transfer can ac-
tively inhibit ovarian tumor growth [7]. In another study,
administration of TILs (alone or in combination with
chemotherapy) was shown to induce objective cancer
regressions [8]. Although adoptive immunotherapy has
much promise, several problems remain to be solved
(reviewed in [5,6,9]).
One major obstacle facing the field of cancer immuno-
therapy is the daunting task of breaking tolerance to
self-antigens. This can be difficult or impossible if the T
cell receptor (TCR) repertoire has been deleted or ren-
dered non-functional by various post-thymic tolerance
mechanisms [10,11]. Several strategies for identifying
therapeutically effective T cell clones and expressing the
operative heterodimeric TCR in patients’ lymphocytes
prior to autologous transplant have been tested
(reviewed in [12-16]). An alternative strategy to produceal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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antigen receptor (CAR) [17] approach.
CARs are fusion molecules comprising an extracellular
binding domain, typically a single-chain variable-frag-
ment antibody (scFv), containing the VH and VL chains
joined by a peptide linker of about 15 residues in length
[18] and intracellular lymphocyte signaling domains
such as CD3ζ, CD28, 4-1BB (CD137), which mediate T
cell activation (reviewed in [14]). CARs bypass a com-
mon immune evasion mechanism of tumor cells, the
downregulation of MHC-I and antigen presentation, and
provide unique opportunities to engineer T cells without
MHC restriction and with potent costimulatory signals.
CAR-T cell therapy targeting FRα
A large number of CARs targeting diverse tumors have
been developed [14]. Although clinical pilot studies are just
beginning, the potential of this form of immunotherapy is
becoming increasingly obvious. A trial of 11 patients with
neuroblastoma treated with CAR-T cells specific for the
GD2 ganglioside showed short-term persistence of CARs
with some evidence of antitumor effects [19]. In another
report, 19 patients were treated with GD2-specific CAR-T
cells, and 3 of 11 achieved remission with long-term per-
sistence of the CARs, which appeared to correlate with
clinical outcome [20]. Initial reports have also documented
remarkable clinical responses in patients with advanced
chronic lymphocytic leukemia (CLL) or lymphoma after
therapy with CD19-specific CAR-T cells [21-25]. There has
been a single study of adoptive transfer of CAR-T cells in
ovarian cancer, with specificity directed against folate
receptor-α (FRα) [26]; while this study demonstrated safety,
the results were disappointing, with no clinical tumor
responses, most likely due to low expression of the trans-
genic CAR, and poor persistence of the transferred T cells.
For the treatment of ovarian cancer, an appropriate
target is the FRα, a membrane protein, which binds folic
acid with high affinity and mediates the cellular uptake
of this vitamin (and drug conjugates thereof ) via
receptor-mediated endocytosis [27]. Subsequent analyses
have shown elevated FRα expression in approximately
90% of ovarian carcinomas, as well as, numerous other
cancers, including endometrial, kidney, lung, mesotheli-
oma, breast, brain, and myeloid leukemia, whereas most
normal tissues express low to negligible levels [28]. This
could be of clinical significance, particularly given the
current development of folate-targeted imaging and
therapeutic agents [29]. Low-level FRα expression in
normal human tissues is limited to the luminal surface
of cells located in the bronchial epithelium, renal tubules
and the choroid plexus, intestinal brush-border mem-
branes, type-1 and type-2 pneumocytes of the lung, and
placental tissue. These folate receptors remain inaccess-
ible to folate and folate conjugates because of theirexclusive localization on the apical surfaces of polarized
epithelia, and consequently, in healthy patients that do
not have malignant masses or an inflammatory disease,
measurable folate conjugate uptake has been limited to
the kidneys where folate salvage occurs [30]. Renal tox-
icity has not been observed in animals or humans trea-
ted with folate-chemotherapeutic agent conjugates
[31,32], antibodies [33]or directed T cells [26,34], how-
ever the acute, transient toxicities associated with ad-
ministration of anti-folates, such as methotrexate, bear
consideration. To date, various folate–drug conjugates
have demonstrated safety and therapeutic value in ani-
mals [8,35] and in phase-I trials [30]. Promising pilot ef-
ficacy data of treating ovarian cancer patients with FRα-
directed T cells was provided by a study of adoptive,
intraperitoneal (IP) transfer of armed autologous T cells
retargeted to FRα using a bispecific monoclonal antibody
containing anti-CD3 and anti-FRα MOv18 F(ab’)2 frag-
ments, in combination with IP interleukin-2 (IL-2) [34].
The overall intraperitoneal response rate was 27%, with
three complete responses lasting 26, 23 and 18 months,
respectively. Adverse events included grade 1–2 fever,
nausea, emesis and fatigue, which appeared related to
IL-2 administration and not to FRα targeting. In the first
reported clinical trial of CAR therapy, administration of
T cells transduced with a MOv18 scFv-directed FRα-spe-
cific CAR harboring no costimulatory domains resulted
in poor persistence of transferred T cells in immuno-
competent recipients in vivo [26]. While this study
demonstrated safety, the results were disappointing, with
no clinically evident tumor responses.
In the proposed study, we will test the safety and effi-
cacy of lymphodepletion followed by adoptive transfer of
autologous T cells transduced with CAR recognizing the
FRα, and carrying the CD3ζ domain along with the
4-1BB costimulatory signaling domain to address the
issue of persistence of FRα-specific CAR-T cells. This
CAR construct was developed by Powell and colleagues
and was tested in an animal model [35]. Preclinical
results show clearly that the anti-FRα CAR outfitted
with intracellular CD3ζ and 4-1BB costimulatory signal-
ing overcomes issues of poor T cell persistence and
tumor localization that limited the previous FRα CAR-T
cell targeting strategy, to provide potent antitumor activ-
ity in vivo [35]. CARs containing the FRα-specific scFv
MOv19 coupled to the T cell receptor CD3ζ chain sig-
naling module alone (MOv19-ζ) or in combination with
the 4-1BB (CD137) costimulatory motif in tandem
(MOv19-BBζ) were directly compared (summarized in
Figure 1). Primary human T cells that were stably trans-
duced with recombinant lentivirus to express a first gen-
eration MOv19-ζ or second generation costimulated
MOv19-BBζ CAR secreted various proinflammatory
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Figure 1 Schematic summary of preclinical results for FRα-specific CAR T cell therapy. (Upper left) Cartoon of first (MOv19-ζ) or second
generation (MOv19-BBζ) FRα-specific CARs bearing CD3ζ alone or in combination with a 4-1BB costimulatory domain, respectively. (Upper right)
Summary of in vitro CAR effects. FRα-specific CAR T cells produce proinflammatory cytokines, proliferate and kill FRα-expressing tumor cells in vitro.
(Lower left) Administration of second generation MOv19-BBζ CAR T cells results in eradication of human FRα ovarian cancer cells in immunodeficient
mice. (Lower right) Tumor regression in vivo was associated with increased human T cell persistence in the blood 3 weeks after infusion.
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ever, only transfer of human T cells expressing the costi-
mulated MOv19-BBζ CAR mediated tumor regression in
immunodeficient mice bearing large, established FRα-
positive human ovarian cancers, while MOv19-ζ CAR-T
cells were ineffective, recapitulating previous clinical
results with FRα CAR T cells lacking costimulatory sig-
nals. MOv19-BBζ CAR-T cell infusion mediated tumor
regression in models of metastatic intraperitoneal, sub-
cutaneous, and lung-involved human ovarian cancer.
Importantly, tumor response was associated with the se-
lective survival and tumor localization of human T cells
in vivo, and was only observed in mice receiving costi-
mulated MOv19-BBζ CAR-T cells. These compelling
data warrant the translation to the clinic, and led us to
design the following phase I protocol.
Trial design
This is a phase I, single-arm, single-center, dose-escalation
study to establish the safety and proof of concept of
autologous FRα-redirected T cells administeredintravenously in subjects with recurrent stage II to IV
FRα-positive epithelial ovarian carcinoma. Subjects
will be 18 years or older diagnosed with advanced
ovarian cancer who have failed two or more prior
chemotherapy regimens, with ECOG ≤2 performance
status, and >3 month expected survival.
This design involves an initial accelerated dose-
escalation phase followed by a standard 3 + 3 escalation
phase. In the initial accelerated phase, cohorts of one
subject will be treated per dose level. The accelerated
phase will end when the first instance of moderate tox-
icity (MT) attributed to T cell reactivity at any dose level
is observed. The cohort at the current dose level will be
expanded and the standard 3 + 3 phase will ensue for all
subsequent cohorts.
The accelerated escalation phase
Consists of one cohort, divided into 3 subcohorts of 1
subject per dose level (Cohorts 1A, 1B, and 1 C). CAR-T
cells will be given to lymphodepleted subjects by a single
intravenous infusion on Day 0. Three dose levels will be
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million CAR-T cells; with the final cohort receiving 30
million CAR-T cells. All doses are +/− 20%, and at least
10% of T cells in the preparation must be CAR-positive
to meet release criteria. In a lymphopenic host, adop-
tively transferred T cells (including CAR-T cells) are
expected to expand exponentially until homeostatic res-
toration of the T cell counts. To contain the exponential
expansion of CAR-T cells and maximize safety, one bil-
lion autologous untransduced peripheral blood lympho-
cytes (PBL) will be administered intravenously on Day 2
to all subjects in the accelerated escalation phase (cohort
1A, 1B, and 1 C). Additional safety benefits will be
derived by the significantly shortened lymphopenia
under this design.
The standard escalation phase
Consists of 4 cohorts, each comprising 3 patients per
dose level. To maximize safety, CAR-T cells will be
dosed using a “split-dose” approach to the intravenous
infusion: 10% on Day 0, 30% on Day 1 and 60% on Day
2. Four dose levels will be given, from 100 million to 1
billion CAR-T cells. Again, to prevent the population of
CAR-T cells from expanding excessively, subjects will be
administered untransduced PBL in a “decrescendo” dose
scheme: cohort 2 will receive 100 million CAR-T cells
followed by 1 billion PBL; cohort 3 will receive 300 mil-
lion CAR-T cells followed by 700 million PBL; cohorts 4
and 5 will recieve 300 million and 1 billion CAR-T cells,
respectively, without any PBL (Figure 2).
Regimen
At entry, subjects will be screened and their eligibility
will be determined. Those who meet all eligibility criteria
will undergo apheresis within 4–6 weeks prior to the
Day 0 visit, in order to obtain peripheral blood mono-
nuclear cells (PBMCs) for CAR-T cell manufacturing.
PBL will be enriched by a process of elutriation [36];
transduced with anti-FR-α scFv CAR; expanded in vitro;
and then frozen for future administration. Subjects will
be allowed to undergo standard of care therapy at the
discretion of the investigator while CAR-T cells are being
manufactured, if clinically indicated due to rapid disease
progression.
Subjects will be enrolled serially, with a minimum of
four weeks elapsing between dosing the last subject of
one dose level to dosing the first subject at the next dose
level. In each cohort, a minimum of three weeks must
elapse (for evaluation of toxicities) after each subject
starts treatment prior to the next subcohort/subject.
Subjects will receive a single course of outpatient lym-
phodepleting chemotherapy with intravenous cyclophos-
phamide (300 mg/m [2]/d for 3 consecutive days) and
intravenous fludarabine (30 mg/m [2]/d for 3consecutive days) prior to T cell administration. Subjects
in cohort 1 will receive 3–30 million CAR-T cells dosed
intravenously 1–3 days after lymphodepletion on Day 0.
Subjects in cohort 2–5 will receive 100 million to 1 bil-
lion CAR-T cells 1–3 days after lymphodepletion (on
Day 0, 1 and 2), using a “split-dose” approach. Subjects
in cohort 1–3 only will receive untransduced autologous
PBL intravenously on Day 2. (Figure 3)
Subjects will be followed daily for the first 5 days
(starting at Day 0), twice weekly until week 4 (~ 28
Days) and weekly until end of study (EOS). After EOS,
the interventional portion of the protocol ends and
long-term follow-up (LTFU) begins. LTFU occurs semi-
annually for up to five years post-infusion and then an-
nually thereafter for up to 15 years after EOS or early
withdrawal.
Subjects will have an optional CT or ultrasound-
guided tumor biopsy at screening, if they have detectable
disease that can be safely accessed, or a needle aspiration
of malignant effusion, to determine if tumor expresses
FRα. Alternatively, archived tumor tissue will be tested.
All subjects will have a mandatory CT or ultrasound-
guided tumor biopsy at EOS, if they have detectable dis-
ease that can be safely accessed, or a needle aspiration of
malignant effusion. Subjects will have end of study 1
visit (EOS1) on ~Day 58. However, subjects with no evi-
dence of response by conventional RECIST (response
evaluation criteria in solid tumors) will be offered to
undergo another CT or MRI 4–8 weeks post Day 58 to
further evaluate tumor burden applying immune-related
response criteria (irRC) [37] to report as a secondary
endpoint.
The trial has been approved by all regulatory boards
and it will be conducted in accordance with the
protocol.
Objectives and endpoints
The primary objective of this study is to determine the
safety and feasibility of the therapy with T cells stably
transduced with the anti-FRα CAR administered intra-
venously following transient lymphodepletion with
cyclophosphamide/fludarabine. The secondary objectives
are to determine anti-tumor response using RECIST
and/or irRC; to assess the distribution of immune
related (ir)-progression-free survival, overall survival and
time to progression; to define a no observable adverse
effect level (NOAEL) or an optimal biologic dose (OBD)
of FRα CAR-T cells; to determine the effect of CAR-T
cells on tumor immunity and FRα expression (for
patients with available pre-treatment tumor sample); de-
termine whether circulating CAR-T cells retain antitu-
mor effects in time; and to evaluate the engraftment of
CAR-T cells in circulation longitudinally in time, and in
tumors at the end of study.
3 million CAR-T 1 billion PBL
30 million CAR-T
10 million CAR-T 1 billion PBL
1 billion PBL
100 million CAR-T 1 billion PBL
300 million CAR-T 700 million PBL
300 million CAR-T 0 PBL
1 billion CAR-T 0 PBL
Accelerated Escalation Phase
Standard Escalation Phase
Figure 2 Clinical trial design: Dose escalation schema.
Kandalaft et al. Journal of Translational Medicine 2012, 10:157 Page 5 of 10
http://www.translational-medicine.com/content/10/1/157Statistical methods
This is a phase-I dose-finding study. The sample size is
based on the numbers of patients needed to find the MTD
and determine with 95% confidence that the toxicity level
at the MTD is less than 33%. Safety of transferring T cells
will be evaluated through the identification of a phase-II
dose using a 3+ 3 standard dose escalation design.
Progression-free and overall survival will be presentedFigure 3 Clinical trial regimen: Schedule of events.graphically using the Kaplan-Meier method. Descriptive
statistics will be applied to determine the relative engraft-
ment, persistence in blood (and optionally trafficking to
tumor) of the CAR-T cells. Number of CAR-T cells in
blood, Human Anti-Chimeric antibody (HACA) levels,
serum cytokine levels and IFN-g ELISPOT measurement
of whole PBL reactivity to FR-α protein will be displayed
graphically as a function of time.
Kandalaft et al. Journal of Translational Medicine 2012, 10:157 Page 6 of 10
http://www.translational-medicine.com/content/10/1/157Translational studies
a) Persistence, engraftment, phenotype and function of
CAR+T cells: Our main translational endpoint is to
determine the fate of FRα-directed CAR+T cells
in vivo. Persistence of T cells post-transfer is a critical
marker of successful engraftment and clinical efficacy
[38]. Conveniently, CAR+T cells can be readily
identified by flow cytometry using PE conjugated goat
anti-mouse IgG F(ab')2 (Jackson ImmunoResearch) as
well as detected by DNA quantitative (q)PCR for
vector copy number in PBMC, an exquisitely sensitive
method to test for persistence of CAR+T cells.
CAR+T cells will be quantified in peripheral blood
longitudinally (2 h post each infusion, daily on Days 4–
9, then weekly x 3, every 4 weeks until Month 6, and
then every 3 months for 2 years. Relevant to T cell
persistence, we will quantify endogenous IL-7 and IL-
15 serum cytokines, which have been implicated in the
expansion and persistence of transferred T cells in the
lymphodepleted host [39], along with a comprehensive
cytokine panel using Luminex. The levels of
endogenous IL-7 following our outpatient CY/FLU
regimen have never been studied and results could
guide decisions related to adding adjuvant cytokines
(see below). CAR+T cells will also be phenotyped for
IL-7 receptor (CD127) and IL-15 receptor alpha
expression.
A second important question relates to the phenotype
and function of CAR+T cells. Phenotypic analysis of
CAR+T cells will include detailed interrogation for
memory cell markers (CCR7, CD62L, CD45RA, CD27,
CD28, Fas, etc.) vs. effector cell markers (CD45R0,
CCR6, CD25, CD38, HLA-DR, GITR, PD-1, etc.), and
among these we will quantify CAR+T cells expressing
inhibitory receptors suggesting exhausted phenotype
(PD-1, LAG-3, TIM-3 etc.). The presence of memory T
cells is a strong predictor of long-term persistence and
efficacy in the human, and in mouse models of adoptive
therapy it has been dramatically enhanced by IL-7 [40].
Phenotypic analysis will be paired with functional ana-
lysis; whole PBL or enriched CAR+T cells will be coin-
cubated with ovarian cancer cells expressing FRα, or
stimulated with PHA-ionomycin, FRα protein or CD3/
CD28 beads as control, followed by interrogation of
intracellular cytokines (INF-γ, TNF-α, MIP-1α, IL-2, IL-
17, IL-4, TGF-β, IL-10), granzymes, CD137 and CD107a.
These will provide a detailed longitudinal character-
ization of in vivo T cell polarization and function post-
transfer. Based on mouse data, we expect these cells to
maintain a Th1 polarization, but it is possible that with
time they exhibit an exhausted phenotype and function
(PD-1+, unable to proliferate and with reduced IL-2 orTNF-α upregulation). These findings will guide future
clinical development. Lastly, the presence of CAR+T
cells will be quantified in tumor biopsies by DNA qPCR
and correlated with tumor FRα protein expression at
baseline and end of study.
b) CAR immunogenicity: We will assess the
development of host immune responses to the CAR T
cells by HAMA, HACA and VSV-G ELISA, and
correlate with engraftment of CAR+T cells. These
results will guide the need for future development of a
CAR bearing a human anti- FRα scFv.
Innovation
This trial introduces several innovations: First, although, a
previous CAR against FRα has been tested, this CAR
introduces the potent costimulatory domain of 4-1BB.
Second, the previous construct utilized a retrovirus, while
this CAR is introduced via a lentivirus. Finally, unlike the
previous trial, this trial will use cytotoxic chemotherapy to
induce transient lymphodepletion. The proposed thera-
peutic approach is novel and has not been previously
tested. In addition to these technological innovations that
take advantage of advances made over the past 10 years
[22,35,41], this trial is introducing a novel adoptive T cell
therapy design that tries to maximize safety and minimize
untoward acute effects, as well as, adverse events from un-
controlled long-term expansion of CAR-T cells that are
infused following lymphodepletion.
CAR-T cells may induce acute infusion reactions and
pathological cytokine responses. On-target acute toxicity
has been observed in some trials using CAR-T cells. A pa-
tient treated with T cells bearing a Her2/neu-specific CAR:
CD28-CD137-ζ died soon after adoptive transfer, probably
due to rapid hyperactivation induced by the recognition of
normal tissue expressing the same antigen [42]. Moreover,
another patient died after preconditioning and adoptive
transfer of T cells bearing a CD19-specific CAR:CD28-ζ,
although, in this case an underlying infection released due
to the cyclophosphamide preconditioning regimen was
the most probable cause of this mortality [43]. To mitigate
these risks we introduced two safety measures: a) Subjects
will receive incrementing doses of CAR-T cells with the
first cohort starting at an unusually low dose of 3 million
T cells, and we will escalate doses by half log increments.
b) CAR-T cells will be dosed using a “split-dose” approach
to the intravenous infusion: 10% on Day 0, 30% on Day 1
and 60% on Day 2.
Furthermore, CAR-T cells may initiate autoimmune at-
tack on normal tissues if their target is expressed in vital
organs and a critical number of self-reactive T cells is
reached. Examples of such self-recognition include myo-
carditis, nephritis, hepatitis or colitis. Although, in the
proposed trial we will start at a very low dose of CAR-T
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lymphodepleted host and eventually they could reach a
critical mass sufficient for auto-reactivity. Indeed, in the
absence of any additional manipulation, the frequency of
CAR-T cells may remain unaltered as adoptive T cells re-
populate the host. When Porter and colleagues infused a
low dose (1.5 × 10 [5] cells per kilogram of body weight)
of autologous anti-CD19 CAR-T cells in a patient with
CLL, these cells expanded over 3 weeks to a level that
was more than 1,000 times as high as the initial engraft-
ment level in vivo. This patient experienced develop-
ment of tumor lysis syndrome only after CAR-T cells
reached a critical threshold several weeks after T cell
transfer, and finally complete remission was achieved.
These engineered cells persisted at high levels for
6 months in the blood and the bone marrow and contin-
ued to express the chimeric antigen receptor.
To maintain a low frequency of CAR-T cells in the
repopulated host, we introduced a design whereby after
uncontrolled expansion of CAR-T cells is allowed for 48
hours, a bulk of untransduced autologous PBL is infused.
Accordingly, subjects in the accelerated escalation phase
(cohort 1) will receive one billion autologous untrans-
duced PBL. To permit incremental expansion of CAR-T
cells, subsequent cohorts will receive “decrescendo”
untransduced PBL (1 billion, 700 million and none). The
innovation lying behind the inclusion of untransduced
PBL introduces a middle ground between completely
lymphodepleting the host, whereby all space is made























Figure 4 Modeling of CAR-T cell expansion in vivo in the lymphodep
untransduced PBL on Day 2.expansion (leading to possible delayed toxicity), and in-
fusing CAR-T cell in a non-depleted host, giving them
no room to expand and thus likely limiting their thera-
peutic potential (Figure 4). If toxicity is still seen despite
the above safety measures, CAR-T cells could also be
controlled with corticosteroids and/or immunosuppres-
sive drugs [44].
Discussion
With compelling evidence that ovarian cancers are im-
munogenic tumors [45] and with the dramatic advances
in laboratory and clinical procedures, new opportunities
have been created for ovarian cancer immunotherapy
[46,47]. In order to be effective, cancer immunotherapy
is dependent on the presence of sufficient numbers of
antitumor lymphocytes with appropriate homing and ef-
fector functions that enable them to seek out and des-
troy cancer cells in vivo. The adoptive transfer of ex vivo
expanded, tumor-reactive T cells holds the potential of
achieving this condition in a short period of time. How-
ever, adoptive T cell immunotherapeutic strategies utiliz-
ing naturally-occurring tumor-reactive T cells are limited
by the availability of such T cells for administration and
the downregulation of MHC class I molecules and anti-
gen processing machinery by the tumor [48]. To obviate
these obstacles CAR-T cells were designed to redirect
the anti-tumor immune response to FRα expressed on
the surface of ovarian cancer cells.
The objective of this study is to implement adoptive






leted host without (above) and with (below) infusion of bulk
Kandalaft et al. Journal of Translational Medicine 2012, 10:157 Page 8 of 10
http://www.translational-medicine.com/content/10/1/157lymphodepletion with cyclophosphamide/fludarabine
and evaluate the safety and feasibility of this treatment
for recurrent ovarian cancer patients. The ultimate goal
of this approach is to induce tumor-specific immune re-
sponse in patients with FRα-positive ovarian cancer and
achieve a prolongation of progression-free survival in
patients with a recurrent disease who otherwise do not
respond to other therapies. We chose folate receptor as
the target antigen because it is expressed at high levels
in 90% of epithelial ovarian carcinoma [49], its expres-
sion is not significantly altered even after chemotherapy
[50], and because it appears to be a safe target [33].
To successfully apply CAR-T cells in the clinic, transi-
ent lymphodepletion is necessary to create a favorable
space and environment for the efficient expansion and
activation of CAR-T cells. Lymphodepletion has many
attributes such as reduction in the number of immuno-
suppressive regulatory T cells and enhancement of the
half-life and effectiveness of adoptive T cell therapy [47].
Lymphodepletion also enhances transiently the availabil-
ity of cytokines such as IL-7 and IL-15 [51]. The benefits
of transient lymphodepletion prior to cell infusion are
observed in an ongoing trial at the University of Penn-
sylvania where patients with myeloma who received au-
tologous CD3/CD28-costimulated T cells 2 days after
Busulfan showed improved engraftment compared to
patients where T cells were given 12 days after chemo-
therapy [52,53].
We will also apply certain safety measures to mitigate
the risks associated with this powerful therapy. We will
start with a very low dose of CAR-T cells; we will admin-
ister higher doses in an incremental split-dose approach;
and finally, we will infuse a large number of autologous
PBLs two days after the CAR-T-infusion to suppress the
potential overexpansion of CAR-T cells and to provide a
safety mechanism.
We expect that FRα-specific CAR-T cells will persist in
circulation for prolonged periods of time, just as it was
seen in recent CD19 CAR trials. This will be evaluated
using the same molecular methods, including flow cyto-
metry and RT-PCR used previously [54]. However, it is
possible that in the CD19 CAR trials, long persistence of
CAR-T cells was allowed by the absence of HAMA due to
the complete ablation of B cells, which ensued CD19
CAR-T cell therapy, as well as chronic antigen stimulation
provided by ever emergent B cells arising from the bone
marrow and attempting to reconstitute the host. In the
proposed trial, the B cell compartment will be intact and
HAMA [55] could develop and shorten the half-life of our
FRα CAR-T cells. In that case, using a human scFv in the
redesign of the CAR will be crucial to enable long-term
engraftment of CAR-T cells.
We expect that the adoptively transferred CAR-T cells
will traffic to the ovarian tumors deposits and willmediate regression of the cancer cells. Lymphocytes have
complex trafficking and survival kinetics, but based on
previous data from a trial with CAR-T cells at the Uni-
versity of Pennsylvania [22] we anticipate that the half-
life of CAR-T cell following single infusion will be longer
than that of normal CD8+ cells (half-life of normal CD8
+ cells is 10 days) and that this therapy will provide a
long lasting effect. Unlike antibody-mediated therapy,
CAR-modified T cells have the potential to replicate and
survive in vivo, and long-term presence could lead to
sustained tumor control.
In summary, we hypothesize that the clinical efficacy
of the proposed CAR-T cell regimen following transient
lymphodepletion will be substantial and that the poten-
tial benefits outweigh the risks. CAR-T cells have been
administered in patients with different types of tumors
in different phase I trials. When patients with CLL were
treated with CAR-T cells, the cell infusions had no acute
toxic effects and the engineered cells persisted at high
levels for 6 months in the blood and bone marrow and
continued to express the CAR. If a lack of dose-limiting
toxicities is confirmed in the present study, we will test
whether exogenous cytokine support (e.g. IL-7) can en-
hance CAR-transduced T cell persistence and expand a
CAR-transduced memory T cell population in vivo fol-
lowing adoptive transfer. A positive outcome from CAR-
T therapy trials in terms of effective therapy, extension
of progression free and overall survival in a recurrent
setting would represent a major advancement for
patients with advanced ovarian cancer.
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